Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Systemic Mastocytosis With an Associated Hematologic Neoplasm: early-phase trial registry
1 of 2 indexed Systemic Mastocytosis With an Associated Hematologic Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Systemic Mastocytosis With an Associated Hematologic Neoplasm: 2 US clinical trials tracked, 1 recruiting.
Systemic Mastocytosis With an Associated Hematologic Neoplasm is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Blueprint Medicines Corporation, running 1 of these trials.
Enrollment posture brief
Registry condition systemic-mastocytosis-with-an-associated-hematologic-neoplasm
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Systemic Mastocytosis With an Associated Hematologic Neoplasm lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Systemic Mastocytosis With an Associated Hematologic Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Systemic Mastocytosis With an Associated Hematologic Neoplasm is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Avapritinib With Decitabine in Patients With SM-AHN
H. Lee Moffitt Cancer Center and Research Institute
NCT06327685
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
NCT03580655
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Systemic Mastocytosis With an Associated Hematologic Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Systemic Mastocytosis With an Associated Hematologic Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Systemic Mastocytosis With an Associated Hematologic Neoplasm page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Systemic Mastocytosis With an Associated Hematologic Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Blueprint Medicines Corporation sponsors the most Systemic Mastocytosis With an Associated Hematologic Neoplasm trials on record, review their full trial history before evaluating a specific study. See Blueprint Medicines Corporation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Systemic Mastocytosis With an Associated Hematologic Neoplasm condition card totals 2 registered trials; most-linked intervention Avapritinib; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.